IRIS
FASANO, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.066
AS - Asia 2.733
NA - Nord America 2.503
SA - Sud America 561
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 4
Totale 8.924
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.454
CN - Cina 1.062
IE - Irlanda 930
UA - Ucraina 713
SG - Singapore 668
SE - Svezia 481
BR - Brasile 452
VN - Vietnam 275
HK - Hong Kong 235
RU - Federazione Russa 233
IN - India 216
FR - Francia 208
FI - Finlandia 186
TR - Turchia 185
DE - Germania 95
IT - Italia 84
GB - Regno Unito 58
AR - Argentina 51
AT - Austria 21
CA - Canada 21
EU - Europa 21
ID - Indonesia 19
MX - Messico 19
EC - Ecuador 17
ZA - Sudafrica 16
CZ - Repubblica Ceca 13
BD - Bangladesh 12
CO - Colombia 11
IQ - Iraq 11
UY - Uruguay 10
BE - Belgio 9
NL - Olanda 9
PK - Pakistan 9
EG - Egitto 8
ES - Italia 7
PY - Paraguay 7
SY - Repubblica araba siriana 7
VE - Venezuela 6
BG - Bulgaria 5
AE - Emirati Arabi Uniti 4
JP - Giappone 4
AZ - Azerbaigian 3
CH - Svizzera 3
IR - Iran 3
KZ - Kazakistan 3
NP - Nepal 3
PE - Perù 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AU - Australia 2
CI - Costa d'Avorio 2
CL - Cile 2
KR - Corea 2
LB - Libano 2
LT - Lituania 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PL - Polonia 2
RO - Romania 2
RS - Serbia 2
SA - Arabia Saudita 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IL - Israele 1
KE - Kenya 1
ML - Mali 1
OM - Oman 1
SN - Senegal 1
TH - Thailandia 1
TN - Tunisia 1
UG - Uganda 1
Totale 8.924
Salva come PNG Salva come JPEG
Città #
Dublin 928
Jacksonville 505
Dearborn 317
Nyköping 298
Nanjing 281
Singapore 269
Chandler 249
Hong Kong 232
Beijing 151
Wilmington 137
Ashburn 123
Dong Ket 117
Santa Clara 114
Dallas 107
Nanchang 102
Princeton 102
San Mateo 79
Helsinki 78
Moscow 78
Shenyang 60
Ho Chi Minh City 59
Hebei 52
Kunming 51
The Dalles 48
Tianjin 44
Jiaxing 37
Munich 37
Hanoi 36
Ann Arbor 35
Changsha 34
Ningbo 29
São Paulo 27
Jinan 26
Stevenage 24
Des Moines 23
New York 21
Zhengzhou 21
Guangzhou 19
Hilden 19
Los Angeles 19
Hangzhou 17
Lanzhou 15
Nuremberg 15
Shanghai 15
Turku 14
Ankara 13
Brno 13
Taizhou 13
Redwood City 12
Rio de Janeiro 12
Vienna 12
Pune 10
Montevideo 9
Quảng Ngãi 9
Woodbridge 9
Brasília 8
Chengdu 8
Foggia 8
San Jose 8
Brussels 7
Guarulhos 7
Johannesburg 7
London 7
Orange 7
San Francisco 7
Belo Horizonte 6
Biên Hòa 6
Boardman 6
Campinas 6
Guayaquil 6
Hefei 6
Montreal 6
Norwalk 6
Ribeirão Preto 6
Al Mansurah 5
Augusta 5
Bari 5
Boston 5
Buenos Aires 5
Cape Town 5
Changchun 5
Curitiba 5
Haiphong 5
Medellín 5
Phoenix 5
Porto Alegre 5
Atlanta 4
Baghdad 4
Belém 4
Bogotá 4
Chandigarh 4
Chicago 4
Dhaka 4
Fairfield 4
Florianópolis 4
Jakarta 4
Leawood 4
Manaus 4
Natal 4
Ninh Bình 4
Totale 5.420
Salva come PNG Salva come JPEG
Nome #
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 188
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 160
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 141
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 132
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 124
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 120
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 117
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 115
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 114
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 111
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 110
Flares during long-term entecavir therapy in chronic hepatitis B 107
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 106
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 106
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 105
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 105
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 104
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 104
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 104
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 103
A proposito di epatite B. News da EASL 2008. 101
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 101
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 100
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 100
Chronic hepatitis B: Advances in treatment. 100
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 99
HBsAg loss is enough to discontinue long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients in real practice 99
Epatite acuta C in un’ampia coorte di pazienti: fattori di rischio ed evoluzione 96
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 96
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 96
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 95
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 94
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 93
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C 92
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 92
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 92
Risposta a lungo termine alla monoterapia con lamivudina in pazienti con epatite cronica B, HBeAg negativa: è opportuno cambiare? 91
Detection of in vivo hepatitis B virus surface antigen mutations-a comparison of four routine screening assays 91
ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS 90
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 90
Nuove strategie di trattamento 90
Reply. 89
Interim analysis of the Italian Master-Entas cohort study: entecavir can improve liver function in patients with chronic hepatitis B and liver cirrhosis 89
Come trattare il paziente con non risposta o risposta virologica parziale 88
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 88
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 88
Malattie causate da Elminti 88
Adefovir resistance patterns in patients with lamivudine resistant chronic hepatitis B 87
Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. 87
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 86
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 85
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 85
Risposta alla terapia con Adefovir Dipivoxil (ADV) in pazienti con Epatite Cronica B, resistenti alla Lamivudina 84
Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding 84
Prediction of hepatocellular carcinoma in entecavir treated patients: results from 744 chronic hepatitis B patients in European Multicenter Study (VIRGIL) 83
Definizione delle resistenze e metodiche di laboratorio 83
Risposta virologica e resistenza ad Adefovir dipivoxil (ADV) in pazienti con Epatite Cronica B resistente alla Lamivudina (LAM) 83
ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 81
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin. 19th International Symposium on Hepatitis C Virus and Related Viruses 81
La genetica dei virus epatitici: implicazioni cliniche e terapeutiche 81
Efficacia e sicurezza della terapia a lungo termine con Entecavir (ETV) o Tenofovir (TDF) in pazienti con cirrosi epatica HBV correlata 81
Diagnostic value of alpha-fetoprotein for early hepatocellular carcinoma diagnosis in cirrhotic HBV patient successfully treated with nucleos(t)ide analogues - a case report 81
Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naive patients with chronic hepatitis B followed for 3 years in a multicenter European study 80
Mutations selected during lamivudine therapy may predispose to adefovir resistance 80
Maintained viral suppression and excellent safety profile of Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study 78
Long-term response to lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B: to change or not to change? 77
Effectiveness of entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 77
Resistance profile of entecavir in patients with chronic hepatitis B 77
Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment 76
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-Interferon α-2b versus a 12-week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with Acute Hepatitis C 76
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 76
Effectiveness of entecavir in field practice: interim analysis of the Italian MASTER-ENTAS cohort study of patients with chronic hepatitis B 76
Risk of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues and long-term virological suppression 76
No beneficial of long-term analogue treatment on the clinical outcome of patients with chronic hepatitis Delta and advanced liver disease. A case-control study. 76
Long-term follow up of patients with acute hepatitis C and spontaneous resolution 75
Early hepatic flares during ETV treatment are rare and do not require treatment adaptation in chronic hepatitis B without cirrhosis 75
Dalla terapia di combinazione Lamivudina+Adefovir alla monoterapia con Tenofovir in pazienti con Epatite Cronica B, HBeAg-negativa: risultati di efficacia e sicurezza 75
Epatite B e Immigrazione 74
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. 74
Studio multicentrico, randomizzato per valutare l’efficacia e la sicurezza di un ciclo di monoterapia con Peg-Interferone alfa-2b della durata di 24 settimane verso un trattamento di 12 settimane di Peg-interferone alfa-2b in monoterapia o in associazione alla ribavirina in pazienti con epatite acuta C 74
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 73
Long-Term HDV-RNA Suppression – HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy 73
HBV e migranti: risultati di uno studio multicentrico SIMIT 73
Efficacia e tollerabilità a lungo termine della monoterapia con entecavir in pazienti con Epatite Cronica B 72
Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months 71
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 71
Epatite acuta C in pazienti in trattamento emodialitico periodico. 70
HBV and immigrants: a SIMIT multicenter cross-sectional study 69
Lack of association between IL28B variants and HBsAg clearance after interferon treatment 68
Entecavir in “real-life”: risultati dello studio VIRGIL 68
HBSAG LOSS IS ENOUGH TO DISCONTINUE LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN REAL PRACTICE? 68
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 67
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 66
ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 65
Terapia a lungo termine con Lamivudina in pazienti con epatite cronica B anti-HBe positiva: quando sospendere? 65
Effectiveness of entecavir for nuc-naive HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 62
Epatiti virali croniche e gravidanza 62
Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 302 NUC-naïve patients with chronic hepatitis B 60
Effectiveness and safety of therapy simplification from Lamivudine + Adefovir to Tenofovir monotherapy in virologically suppressed HBeAg-negative chronic hepatitis B patients 59
I farmaci che bloccano l'entrata dell'HBsAg nell'epatocita: ruolo clinico 56
Totale 8.866
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.097
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.097
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021566 0 0 0 0 0 9 121 21 119 118 28 150
2021/2022554 74 8 7 9 73 32 15 54 66 68 16 132
2022/20231.856 237 91 58 76 53 138 2 126 1.021 17 21 16
2023/2024189 34 10 7 13 18 41 26 8 3 3 1 25
2024/20251.331 68 3 9 14 8 187 201 74 384 63 180 140
2025/20261.395 152 142 458 569 70 4 0 0 0 0 0 0
Totale 9.224